Assertio Completes Zydus Lifesciences Merger, Triggers Convertible Note Fundamental Change
Summary
Assertio Holdings announced the completion of its merger with Zydus Lifesciences. This finalizes the acquisition, which was initially announced on May 13th for $23.50 per share, and follows the successful tender offer indicated in SEC filings earlier today. The completion means Assertio will cease to be an independent public company. This event also triggers a "Fundamental Change" and "Make-Whole Fundamental Change" for its outstanding 6.50% Convertible Senior Notes due 2027, impacting bondholders.
At the time of this announcement, ASRT was trading at $23.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $151.9M. The 52-week trading range was $8.61 to $23.50. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.